In forceCurrent to September 30, 2026 (Justice Canada: October 19)Justice Canada’s site has a later update, which this text may not include yet: Agora reads it from Justice Canada’s GitHub repository, which has not received it.5 amendments not yet in forceHistory
Things that Fall Within Definition “Food” in Section 2
Item
Description
PART 2
Things that Fall Within Definition “Drug” in Section 2
Item
Description
PART 3
Things that Fall Within Definition “Cosmetic” in Section 2
Item
Description
PART 4
Things that Fall Within Definition “Device” in Section 2
Item
Description
2019, c. 29, s. 178
.
SCHEDULE A.1(Section 3)
Acute alcoholism
Alcoolisme aigu
Acute anxiety state
État anxieux aigu
Acute infectious respiratory syndromes
Syndromes respiratoires infectieux aigus
Acute, inflammatory and debilitating arthritis
Arthrite aiguë, inflammatoire et débilitante
Acute psychotic conditions
Troubles psychotiques aigus
Addiction (except nicotine addiction)
Dépendance (sauf la dépendance à la nicotine)
Appendicitis
Appendicite
Arteriosclerosis
Artériosclérose
Asthma
Asthme
Cancer
Cancer
Congestive heart failure
Insuffisance cardiaque congestive
Convulsions
Convulsions
Dementia
Démence
Depression
Dépression
Diabetes
Diabète
Gangrene
Gangrène
Glaucoma
Glaucome
Haematologic bleeding disorders
Affections hématologiques hémorragiques
Hepatitis
Hépatite
Hypertension
Hypertension
Nausea and vomiting of pregnancy
Nausées et vomissements de la grossesse
Obesity
Obésité
Rheumatic fever
Rhumatisme articulaire aigu
Septicemia
Septicémie
Sexually transmitted diseases
Maladies transmises sexuellement
Strangulated hernia
Hernie étranglée
Thrombotic and Embolic disorders
Maladies thrombotiques et embolies
Thyroid disease
Glande thyroïdienne (affections)
Ulcer of the gastro-intestinal tract
Ulcères des voies gastro-intestinales
R.S., 1985, c. F-27, Sch. A
SOR/88-252
SOR/89-503
SOR/90-655
SOR/92-198
SOR/94-287
SOR/99-413, 414
SOR/2007-289, ss. 1, 2
2019, c. 29, s. 177
.
SCHEDULE B(Section 10)
The most recent editions, including all errata, supplements, revisions and addenda, of the following standards:
Column I
Column II
Item
Name
Abbreviation
1
European Pharmacopoeia
(Ph.Eur.)
2
Pharmacopée française
(Ph.F.)
3
Pharmacopoeia Internationalis
(Ph.I.)
4
The British Pharmacopoeia
(B.P.)
5
The Canadian Formulary
(C.F.)
6
The National Formulary
(N.F.)
7
The Pharmaceutical Codex: Principles and Practices of Pharmaceuticals
8
The United States Pharmacopoeia
(U.S.P.)
R.S., 1985, c. F-27, Sch. B
SOR/85-276
SOR/89-315
SOR/90-160
SOR/94-288
SOR/95-530, s. 2
SOR/96-96
.
SCHEDULE C(Section 12)
Drugs, other than radionuclides, sold or represented for use in the preparation of radiopharmaceuticals
Drogues...
Radiopharmaceuticals
Produits pharmaceutiques radioactifs
R.S., c. F-27, Sch. C
SI/72-44
SI/76-1
SOR/79-237
SOR/81-195, 332
SOR/82-769
.
SCHEDULE D(Section 12)
Allergenic substances used for the treatment or diagnosis of allergic or immunological diseases
Substances...
Anterior pituitary extracts
Extraits hypophysaires (lobe antérieur)
Aprotinin
Aprotinine
Cholecystokinin
Cholécystokinine
Drugs obtained by recombinant DNA procedures
Drogues obtenues...
Drugs, other than antibiotics, prepared from micro-organisms
Drogues, sauf...
Drugs that are or are made from blood
Drogue qui est...
Glucagon
Glucagon
Gonadotrophins
Gonadotrophines
Immunizing agents
Agents immunisants
Insulin
Insuline
Interferon
Interféron
Monoclonal antibodies, their conjugates and derivatives
Anticorps monoclonaux et leurs dérivés et conjugués
Secretin
Sécrétine
Snake Venom
Venin de serpent
Urokinase
Urokinase
R.S., 1985, c. F-27, Sch. D
SOR/85-715, s. 1
SOR/89-177
SOR/93-64
SOR/97-560
SOR/2007-120
SOR/2013-180
.
SCHEDULE E(Section 13)
[There are no items in this Schedule.]
R.S., c. F-27, Sch. E
SOR/77-824
SOR/82-769
.
SCHEDULE F(Section 15)
[There are no items in this Schedule of the FOOD AND DRUGS ACT.]
R.S., c. F-27, Sch. F
SOR/84-566
.
SCHEDULE G(Sections 2 and 21.91)
Item
Description
R.S., 1985, c. F-27, Sch. G
SOR/92‑387
1996, c. 19, s. 82
2019, c. 29, s. 179
.
SCHEDULE H
[Repealed, 1996, c. 19, s. 82]
RELATED PROVISIONS
— R.S., 1985, c. 27 (1st Supp.), s. 208
Writs of Assistance
208 Nothing in sections 190, 195, 199 and 200 of this Act shall be construed as rendering invalid or inadmissible in any proceedings any evidence obtained by the exercise of a writ of assistance prior to the coming into force of those sections.
— 1997, c. 6, s. 66(2)
Transitional
66(2) For greater certainty, the two year limitation period provided for in subsection 32(1) of the Act, as amended by subsection (1), only applies in respect of offences committed after the coming into force of that subsection.
— 2005, c. 42, s. 4
Deeming provision
4 A Notice of Interim Marketing Authorization that is issued under the Food and Drug Regulations before the day on which this section comes into force, in respect of any matter referred to in subsection 30.2(2) of the Food and Drugs Act, as enacted by section 3 of this Act, and that is in effect on the day on which this section comes into force, is deemed to be an interim marketing authorization issued under subsection 30.2(1) of that Act.
— 2005, c. 42, s. 5(1)
Pest control products
5(1) The maximum residue limit established for an agricultural chemical and its derivatives under the Food and Drug Regulations, as those regulations read immediately before the coming into force of this subsection, is deemed, if the agricultural chemical is a pest control product as defined in subsection 2(1) of the Pest Control Products Act, chapter 28 of the Statutes of Canada, 2002, to have been specified by the Minister under section 9 or 10 of that Act as the maximum residue limit for that agricultural chemical and its derivatives.
— 2012, c. 19, s. 417
Interim marketing authorization
417(1) An interim marketing authorization that is issued under subsection 30.2(1) of the Food and Drugs Act and in effect immediately before the day on which section 416 comes into force continues to have effect until the earliest of
(a) the day on which the Minister of Health publishes a notice cancelling the interim marketing authorization in the Canada Gazette;
(b) the day on which a marketing authorization — or any part of it — that is issued under subsection 30.3(1) of the Food and Drugs Act, as enacted by section 416, has the same effect as the interim marketing authorization; and
(c) two years after the day on which the interim marketing authorization is published in the Canada Gazette.
(2) A notice cancelling an interim marketing authorization is exempt from sections 3, 5 and 11 of the Statutory Instruments Act.
— 2014, c. 24, s. 13
Therapeutic product authorizations
13 The definition therapeutic product authorization, as enacted by subsection 2(3), applies to authorizations — including licences and suspended authorizations or licences — that were issued before the day on which this section comes into force and that authorize, as the case may be, the import, sale, advertisement, manufacture, preparation, preservation, packaging, labelling, storage or testing of a therapeutic product.
— 2019, c. 29, s. 180
Clinical trials — certain drugs
180 A person that, immediately before the coming into force of section 166, is authorized under Division 5 of Part C of the Food and Drug Regulations to sell or import a drug for the purposes of a clinical trial is deemed to be the holder, in respect of that drug, of an authorization referred to in section 3.1 of the Food and Drugs Act, as enacted by that section 166.
— 2019, c. 29, s. 181
Studies — positron-emitting radiopharmaceuticals
181 A person that, immediately before the coming into force of section 166, is authorized under Division 3 of Part C of the Food and Drug Regulations to sell or import a positron-emitting radiopharmaceutical for the purposes of a study is deemed to be the holder, in respect of that positron-emitting radiopharmaceutical, of an authorization referred to in section 3.1 of the Food and Drugs Act, as enacted by that section 166.
— 2019, c. 29, s. 182
Clinical trials — natural health products
182 A person that, immediately before the coming into force of section 166, is authorized under Part 4 of the Natural Health Products Regulations to sell or import a natural health product for the purposes of a clinical trial is deemed to be the holder, in respect of that natural health product, of an authorization referred to in section 3.1 of the Food and Drugs Act, as enacted by that section 166.
— 2019, c. 29, s. 183
Investigational testing — certain medical devices
183 A person that, immediately before the coming into force of section 166, is authorized under Part 3 of the Medical Devices Regulations to sell or import a Class II, III or IV medical device for investigational testing is deemed to be the holder, in respect of the device, of an authorization referred to in section 3.1 of the Food and Drugs Act, as enacted by that section 166.
— 2022, c. 17, s. 76
Clarification — immediate application
76 For greater certainty, but subject to sections 77 and 78, the amendments made by this Act also apply with respect to proceedings that are ongoing on the day on which this Act comes into force.
— 2022, c. 17, par. 77(2)(a)
Certain applications for warrants
77(2) Each of the following provisions, as it read immediately before the day on which this Act comes into force, continues to apply with respect to an application made for a warrant under the provision if the application is submitted, and no decision has been made in respect of the application, before that day:
78.1(1) The Minister of Justice must, no later than three years after the day on which this Act receives royal assent, initiate one or more independent reviews on the use of remote proceedings in criminal justice matters that must include an assessment of whether remote proceedings
(a) enhance, preserve or adversely affect access to justice;
(b) maintain fundamental principles of the administration of justice; and
(c) adequately address the rights and obligations of participants in the criminal justice system, including accused persons.
Report
(2) The Minister of Justice must, no later than five years after the day on which a review is initiated, cause a report on the review — including any findings or recommendations resulting from it — to be laid before each House of Parliament.
— 2022, c. 17, s. 78.2
Review by committee
78.2(1) At the start of the fifth year after the day on which this Act receives royal assent, the provisions enacted or amended by this Act are to be referred to a committee of the Senate and a committee of the House of Commons that may be designated or established for the purpose of reviewing the provisions.
Report
(2) The committees to which the provisions are referred are to review them and the use of remote proceedings in criminal justice matters and submit reports to the Houses of Parliament of which they are committees, including statements setting out any changes to the provisions that they recommend.
— 2023, c. 26, s. 503
Authorizations and licences
503 The definition therapeutic product authorization in section 2 of the Food and Drugs Act also includes
(a) an authorization, including a licence, that was issued, before the day on which this section comes into force, under the regulations made under that Act and that authorizes, as the case may be, the import, sale, manufacture, packaging or labelling of a natural health product, within the meaning of the Natural Health Products Regulations as those Regulations read immediately before that day; or
(b) an authorization, including a licence, that would fall within paragraph (a) if the authorization were not suspended.
— 2024, c. 17, s. 332
Marketing authorizations
332 Marketing authorizations issued under section 30.2 or 30.3 of the Food and Drugs Act, as those sections read immediately before the day on which section 330 comes into force, that have not been repealed before that day are deemed to be made under subsection 30.05(1) of that Act.
AMENDMENTS NOT IN FORCE
— 2023, c. 12, s. 64
64 The Food and Drugs Act is amended by adding the following after section 11:
Risk to environment
11.1 It is prohibited for a person to sell, or to manufacture, prepare, preserve, package or store for sale, any drug that contains a prescribed substance, unless the Minister has conducted an assessment, in accordance with the regulations made under paragraph 30(1)(l.1), of the risk to the environment presented by the substance.
(5) Paragraph 30(1)(l.1) of the Act is replaced by the following:
(l.1) respecting the assessment of the risk to the environment or human life and health of the release into the environment of any food, drug, cosmetic or device;
(l.2) respecting, for the purpose of managing risks to the environment identified as part of an assessment under this Act, measures in respect of selling or importing, manufacturing, preparing, preserving, packaging or storing for sale any food, drug, cosmetic or device;
(l.3) authorizing the Minister to waive any requirement respecting the assessment under this Act of the risk to the environment presented by a food, drug, cosmetic or device;
(6) Section 30 of the Act is amended by adding the following after subsection (1):
Relevant factor
(1.01) Before recommending to the Governor in Council that a regulation be made under paragraph (1)(a.02), the Minister must take into account the degree of uncertainty respecting the risks to the environment associated with the use of a substance as an ingredient in a drug, including its release into the environment.
327(1) Section 30.05 of the Act is amended by adding the following after subsection (1):
Exemption — person
(1.1) Subject to subsection (2) and any regulations made under paragraph 30(1)(j.1), the Minister may, by order, on any conditions that the Minister considers necessary, exempt a person — or any food, therapeutic product or activity, or any class of foods, therapeutic products or activities, in relation to a person — from the application of all or any of the provisions of Part I, section 37 or the regulations. The order cannot relate to cosmetics.
(2) The portion of subsection 30.05(2) of the Act before paragraph (a) is replaced by the following:
Preconditions
(2) The Minister may make an order under subsection (1) or (1.1) only if the Minister believes on reasonable grounds that
(3) Section 30.05 of the Act is amended by adding the following after subsection (3):
(4) An order made under subsection (1.1) that applies to only one person is not a statutory instrument within the meaning of the Statutory Instruments Act.
Availability — person-specific orders
(5) The Minister must ensure that any order made under subsection (1.1) is publicly available but may exclude personal information and confidential business information from the order.
Unofficial reproduction of the consolidated text published by the Department of Justice Canada, permitted by the Reproduction of Federal Law Order. Only the official text is authoritative.